Epidemiology of movement disorders

Philip A Hanna MD (Dr. Hanna of New Jersey Neuroscience Institute at JFK Medical Center and Seton Hall University School of Graduate Medical Education received honorariums from GlaxoSmithKline, Lundbeck, and Teva for speaking engagements.)
Lesly G Aguilar Tabora MD (

Dr. Aguilar Tabora of Scripps Memorial Hospital La Jolla has no relevant financial relationships to disclose.

Tasneem Peeraully MBBS BSc (Dr. Peeraully of New Jersey Neuroscience Institute at JFK Medical Center has no relevant financial relationships to disclose.)
Joseph Jankovic MD, editor. (

Dr. Jankovic, Director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine, received research and training funding from Allergan, F Hoffmann-La Roche, Medtronic Neuromodulation, Merz, Neurocrine  Biosciences, Nuvelution, Revance, and Teva and consulting/advisory board honorariums from Abide, Lundbeck, Retrophin, Parexel, Teva, and Allergan.

Originally released January 16, 2006; last updated March 6, 2012; expires March 6, 2015
Notice: This article has expired and is therefore not available for CME credit.


In this article, the authors review the epidemiology of Parkinson disease, atypical parkinsonian syndromes, primary dystonias, essential tremor, hemifacial spasm, Huntington disease, Tourette syndrome, and myoclonus.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology